Skip to content

Splenic Marginal Zone Lymphoma C0349632

Published: July 22, 2026Updated: August 20, 2026

A slow-growing blood cancer that starts in the spleen affecting certain white blood cells. Usually occurs in older adults. Often managed with observation or spleen removal.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Splenomegaly

(hematologic)

Fatigue

(hematologic)

Cytopenia

(hematologic)

Night sweats

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Active surveillance

Regular monitoring without immediate intervention for early-stage or asymptomatic disease. Includes periodic imaging, blood work, and clinical evaluation to detect progression before initiating treatment.

monitoring
2

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Splenectomy

Surgical removal of the spleen remains a cornerstone treatment for symptomatic splenomegaly or cytopenias in splenic marginal zone lymphoma. Can result in prolonged remission and hematologic improvement.

surgical

Additional treatment options

Rituximab-based therapy

Anti-CD20 monoclonal antibody used alone or in combination with chemotherapy agents. Provides effective disease control with manageable side effect profile, making it suitable for various patient populations.

medication

Bendamustine plus rituximab

Combination immunochemotherapy regimen combining bendamustine with rituximab for patients requiring systemic treatment. This regimen has demonstrated efficacy in marginal zone lymphoma with manageable toxicity.

medication

Infection prophylaxis

Preventive antimicrobial therapy and vaccination strategy for patients with splenectomy or those receiving immunosuppressive treatment. Includes coverage for encapsulated bacteria and specific vaccines.

medication

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Splenic Marginal Zone Lymphoma C0349632?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020.

guideline2020View source →
2

Kalpadakis C, Pangalis GA, Sachanas S, et al. Splenic marginal zone lymphoma: current knowledge and future directions. Leuk Lymphoma. 2018.

review2018View source →
3

Iannitto E, Tripodo C, Ferreri AJ, et al. Rituximab plus bendamustine in untreated indolent B-cell lymphomas: a phase II study for splenic marginal zone lymphoma. Blood. 2016.

clinical_trial2016View source →
4

Piras IS, Bruscaggin A, Spina V, et al. Molecular pathogenesis of splenic marginal zone lymphoma. Haematologica. 2021.

review2021View source →

Medication Comparisons

Compare medications used to treat Splenic Marginal Zone Lymphoma C0349632. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy